GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Reviva Pharmaceuticals Holdings Inc (NAS:RVPHW) » Definitions » Return-on-Tangible-Asset

Reviva Pharmaceuticals Holdings (Reviva Pharmaceuticals Holdings) Return-on-Tangible-Asset : -159.88% (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Reviva Pharmaceuticals Holdings Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Reviva Pharmaceuticals Holdings's annualized Net Income for the quarter that ended in Mar. 2024 was $-29.74 Mil. Reviva Pharmaceuticals Holdings's average total tangible assets for the quarter that ended in Mar. 2024 was $18.60 Mil. Therefore, Reviva Pharmaceuticals Holdings's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2024 was -159.88%.

The historical rank and industry rank for Reviva Pharmaceuticals Holdings's Return-on-Tangible-Asset or its related term are showing as below:

RVPHW' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -28233.33   Med: -112.31   Max: -42.43
Current: -297.74

During the past 5 years, Reviva Pharmaceuticals Holdings's highest Return-on-Tangible-Asset was -42.43%. The lowest was -28233.33%. And the median was -112.31%.

RVPHW's Return-on-Tangible-Asset is ranked worse than
94.2% of 1551 companies
in the Biotechnology industry
Industry Median: -40.48 vs RVPHW: -297.74

Reviva Pharmaceuticals Holdings Return-on-Tangible-Asset Historical Data

The historical data trend for Reviva Pharmaceuticals Holdings's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Reviva Pharmaceuticals Holdings Return-on-Tangible-Asset Chart

Reviva Pharmaceuticals Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Asset
-28,233.33 -86.32 -42.43 -112.31 -184.22

Reviva Pharmaceuticals Holdings Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -172.24 -402.30 -487.13 -267.45 -159.88

Competitive Comparison of Reviva Pharmaceuticals Holdings's Return-on-Tangible-Asset

For the Biotechnology subindustry, Reviva Pharmaceuticals Holdings's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Reviva Pharmaceuticals Holdings's Return-on-Tangible-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Reviva Pharmaceuticals Holdings's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Reviva Pharmaceuticals Holdings's Return-on-Tangible-Asset falls into.



Reviva Pharmaceuticals Holdings Return-on-Tangible-Asset Calculation

Reviva Pharmaceuticals Holdings's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-39.261/( (18.924+23.7)/ 2 )
=-39.261/21.312
=-184.22 %

Reviva Pharmaceuticals Holdings's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=-29.736/( (23.7+13.497)/ 2 )
=-29.736/18.5985
=-159.88 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Mar. 2024) net income data.


Reviva Pharmaceuticals Holdings  (NAS:RVPHW) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Reviva Pharmaceuticals Holdings Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Reviva Pharmaceuticals Holdings's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Reviva Pharmaceuticals Holdings (Reviva Pharmaceuticals Holdings) Business Description

Traded in Other Exchanges
Address
19925 Stevens Creek Boulevard, Suite 100, Cupertino, CA, USA, 95014
Reviva Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, respiratory, and metabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, 1) Brilaroxazine (RP5063) which is in clinical development and is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and 2) RP1208.